Ubs Group Ag Blueprint Medicines Corp Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ubs Group Ag holds 2,167,028 shares of BPMC stock, worth $281 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
2,167,028
Previous 213,805
913.55%
Holding current value
$281 Million
Previous $18.9 Million
1367.89%
% of portfolio
0.05%
Previous 0.0%
Shares
34 transactions
Others Institutions Holding BPMC
# of Institutions
401Shares Held
67.4MCall Options Held
1.12MPut Options Held
1.67M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.42MShares$831 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL3.9MShares$505 Million3.34% of portfolio
-
Jpmorgan Chase & CO New York, NY2.51MShares$324 Million0.02% of portfolio
-
State Street Corp Boston, MA2.23MShares$289 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...